NCT05925920 is a Phase 1 clinical trial of ENT-03 in Obesity, sponsored by Metabolics Pharma.

Who is sponsoring NCT05925920?

NCT05925920 is sponsored by Metabolics Pharma.

What drugs are being tested in NCT05925920?

Interventions in NCT05925920: ENT-03, Placebo.

What condition does NCT05925920 study?

NCT05925920 studies Obesity, Diabetes Mellitus, Type 2.

Is NCT05925920 still recruiting?

NCT05925920 is currently active, enrolled. Last updated 5 November 2024.

Last reviewed 2024-11-05 · How we verify

NCT05925920

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes

Active, enrolled Phase 1 Last updated 5 November 2024

What this trial tests

Phase 1 trial testing ENT-03 in Obesity in 49 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

13 June 2023

Primary endpoint
12 August 2024

6 December 2024

Quick facts

Lead sponsor	Metabolics Pharma
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	triple
Primary purpose	other
Enrollment	49
Start date	13 June 2023
Primary completion	12 August 2024
Estimated completion	6 December 2024
Sites	1 location across United States

Drugs / interventions tested

ENT-03 — full drug profile →
Placebo

Conditions studied

Obesity — all drugs for Obesity →
Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Metabolics Pharma

Who can join

Adults 18 to 70, any sex, with Obesity or Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Single center, single-dose, randomized, placebo-controlled, dose-escalating study to evaluate, safety, tolerability, pharmacokinetics, and pharmacodynamics of escalating doses of ENT-03S in obese but otherwise healthy subjects and in subjects with obesity and Type 2 diabetes.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy.
Nicze M, Dec A, Borówka M, Krzyżak D, et al · · 2024 · cited 9× · PMID 39125772 · DOI 10.3390/ijms25158202

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05925920 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Metabolics Pharma
Last refreshed: 5 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05925920.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing